Company (location) |
Product |
Description |
Indication |
Status |
Date |
|
Cancer | ||||||
Abbvie Inc., of North Chicago |
Venclexta (venetoclax) |
Oral Bcl-2 inhibitor |
Newly diagnosed acute myeloid leukemia |
Submitted a supplemental NDA for use in combination with a hypomethylating agent or in combination with low-dose cytarabine in patients who are ineligible for intensive chemotherapy |
7/12/18 |
|
Advaxis Inc., of Princeton, N.J. |
Axalimogene filolisbac |
Vaccine comprising Listeria monocytogenes |
Metastatic cervical cancer |
Plans to withdraw its conditional MAA in the EU for use in patients who progress beyond first-line therapy; decision is based on EMA feedback following initial review, indicating the application will likely need additional data |
7/10/18 |
|
Advaxis Inc., of Princeton, N.J. |
ADXS-HOT |
Immunotherapy |
Non-small-cell lung cancer |
FDA cleared the IND for a phase I/II trial; first patient to be dosed by the end of 2018 |
7/30/18 |
|
Agios Pharmaceuticals Inc. (Cambridge, Mass.) |
Tibsovo |
Ivosidenib; formerly AG-120; oral |
Relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation |
FDA granted approval for use with the Abbott Realtime IDH1 test; Tibsovo had priority review, as well as fast-track and orphan drug designations |
7/23/18 |
|
Array Biopharma Inc., of Boulder, Colo. |
Braftovi (encorafenib) plus Mektovi (binimetinib) |
Oral small-molecule BRAF kinase inhibitor and oral small-molecule MEK inhibitor |
Unresectable or metastatic melanoma with a BRAF mutation |
EMA's CHMP issued a positive recommendation for use of the drugs in adults; final EC decision expected by the end of September |
7/27/18 |
|
Astrazeneca plc, of Cambridge, Mass. |
Tagrisso (osimertinib) |
Third-generation, irreversible EGFR tyrosine kinase inhibitor |
First-line locally advanced or metastatic non-small-cell lung cancer |
Approved by Health Canada for patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) |
7/12/18 |
|
Astrazeneca plc, of Cambridge, U.K. |
Imfinzi (durvalumab) |
Anti-PD-L1 antibody |
Locally advanced, unresectable non-small-cell lung cancer |
EMA's CHMP recommended approval for use in adults whose tumors express PD-L1 on ≥1% of tumor cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy |
7/27/18 |
|
Astrazeneca plc, of Dublin |
Imfinzi (durvalumab) |
PD-L1-targeting antibody |
Non-small-cell lung cancer |
Approved by Japan's Ministry of Health, Labour and Welfare for use as a maintenance therapy after definitive chemoradiation therapy in patients with locally advanced (stage III), unresectable disease |
7/2/18 |
|
Astrazeneca plc, of Dublin, and Merck & Co. Inc., of Kenilworth, N.J. |
Lynparza (olaparib) |
PARP inhibitor |
Breast cancer |
Approved by Japan's PMDA for use in patients with unresectable or recurrent BRCA-mutated, HER2-negative disease who have received prior chemotherapy; patients are selected for therapy based on an approved companion diagnostic |
7/2/18 |
|
Beigene Ltd., of Beijing |
Zanubrutinib |
BTK inhibitor |
Waldenström macroglobulinemia |
FDA granted fast track designation |
7/22/18 |
|
Bristol-Myers Squibb Co., of New York |
Opdivo (nivolumab) |
Anti-PD-1 antibody |
Melanoma with involvement of lymph nodes or metastatic disease in patients who have undergone complete resection |
European Commission granted marketing authorization |
7/31/18 |
|
Bristol-Myers Squibb Co., of New York |
Opdivo (nivolumab)/Yervoy (ipilimumab) |
Anti-PD-1 antibody/anti-CTLA-4 antibody |
Intermediate/poor-risk advanced or metastatic renal cell carcinoma |
Combination therapy was approved by Health Canada for use in adults |
7/9/18 |
|
Bristol-Myers Squibb Co., of Princeton |
Opdivo (nivolumab)/Yervoy (ipilimumab) |
Anti-PD-1 antibody/Anti-CTLA-4 antibody |
Microsatellite instability high or mismatch repair deficient metastatic colorectal cancer |
Approved by FDA for use in adult and pediatric patients whose disease has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan; approval was granted under the accelerated pathway based on overall response rate and duration of response |
7/11/18 |
|
Bristol-Myers Squibb Co., of Princeton, N.J. |
Sprycel |
Dasatinib |
Chronic myeloid leukemia |
EC expanded the indication to include treatment of children and adolescents ages 1 to 18 with Philadelphia chromosome-positive CML in chronic phase, and to include a powder for oral suspension formulation |
7/6/18 |
|
Cellectar Biosciences Inc., of Madison, Wis. |
CLR-131 |
Phospholipid drug conjugate |
Ewing's sarcoma |
FDA granted orphan designation |
7/9/18 |
|
Celyad SA, of Mont-Saint-Guibert, Belgium |
CYAD-101 |
Allogeneic CAR T candidate encoding CYAD-01 CAR T and peptide TCR inhibiting molecule |
Unresectable colorectal cancer |
FDA accepted the IND for the Allo-SHRINK trial testing safety and clinical activity in combination with standard chemotherapy |
7/24/18 |
|
Clovis Oncology Inc., of Boulder, Colo. |
Rubraca (rucaparib) |
PARP inhibitor |
Epithelial ovarian, fallopian tube or primary peritoneal cancer |
EMA validated the application for a type II variation for the marketing authorization to include maintenance treatment of adult patients who are in complete or partial response to platinum-based chemotherapy |
7/5/18 |
|
Clovis Oncology Inc., of Boulder, Colo. |
Rubraca |
Rucaparib |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
EMA validated the application for a type II variation to the marketing authorization for Rubraca (rucaparib) to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
7/5/18 |
|
Cstone Pharmaceuticals (Suzhou) Co. Ltd., of Suzhou, China |
CS-1003 |
Anti-PD-1 monoclonal antibody |
Advanced cancers |
China's CNDA approved the first clinical trial application |
7/12/18 |
|
Cstone Pharmaceuticals Co. Ltd., of Suzhou, China |
CS-3006 |
Small-molecule MEK inhibitor |
Cancer |
IND cleared by the CNDA in China |
7/30/18 |
|
Eagle Pharmaceuticals Inc., of Woodcliff Lake, N.J. |
Bendeka |
Bendamustine hydrochloride injection |
Chronic lymphocytic leukemia |
FDA granted 7 years of orphan drug exclusivity |
7/9/18 |
|
Eisai Co. Ltd., of Tokyo, and Merck & Co. Inc., of Kenilworth, N.J. |
Lenvima (lenvatinib) |
VEGFR1, VEGFR2 and VEGFR3 kinase inhibitor |
Second-line or later advanced and/or metastatic non-microsatellite instability high/proficient mismatch repair endometrial carcinoma |
FDA granted breakthrough designation for use with Keytruda (pembrolizumab) |
7/31/18 |
|
Eusa Pharma Ltd., of Hemel Hempstead, U.K. |
Qarziba (dinutuximab beta) |
Immunotherapy |
High-risk neuroblastoma |
Recommended by the U.K.'s National Institute for Health and Care Excellence for use in children in England and Wales |
7/12/18 |
|
Genentech, of South San Francisco, a unit of Roche Holding AG |
Tecentriq (atezolizumab) |
PD-L1-inhibiting antibody |
Urothelial cancer |
FDA posted its June 19 action in which it limited the drug's use to patients with locally advanced or metastatic disease who are not eligible for cisplatin-containing therapy; decision was based on data showing decreased survival with Tecentriq as a monotherapy vs. platinum-based chemotherapy in patients who have not received prior therapy and have low expression of PD-L1 |
7/3/18 |
|
Genmab A/S, of Copenhagen, and Janssen Pharmaceutical Cos., of Beerse, Belgium, part of Johnson & Johnson |
Darzalex (daratumumab) |
Biologic targeting CD38 |
Multiple myeloma |
EMA's CHMP recommended broadening the use for front-line therapy, in combination with bortezomib, melphalan and prednisone, in adults with newly diagnosed disease ineligible for autologous stem cell transplant |
7/27/18 |
|
Immuno-medics Inc., of Morris Plains, N.J. |
Sacituzumab govitecan |
Antibody-drug conjugate targeting TROP-2 |
Metastatic triple-negative breast cancer |
FDA accepted the BLA and granted a priority review with a target action date of Jan. 18, 2019 |
7/18/18 |
|
Immutep Ltd., of Sydney |
Eftilagimod alpha |
LAG-3Ig fusion protein |
Non-small-cell lung carcinoma or head and neck carcinoma |
FDA approved IND for TACTI-002 study testing the drug in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) |
7/30/18 |
|
Innovent Biologics Inc., of Suzhou, China |
IBI-101 |
Anti-OX40 agonistic antibody |
Cancer and hepatitis B |
Received IND approval from Chinese regulators |
7/26/18 |
|
JHL Biotech Co. Ltd., of Hsinchu, Taiwan |
JHL-1101 |
Rituximab biosimilar |
Diffuse large B-cell lymphoma |
Received scientific advice from the EMA's CHMP related to the EU approval pathway; the agency confirmed it agrees with JHL's development approach, clinical development proposal, and study design of the global phase III study |
7/9/18 |
|
JHL Biotech Inc., of Hsinchu, Taiwan |
JHL-1101 |
Rituximab biosimilar |
Non-Hodgkin lymphoma |
The Center for Drug Evaluation, State Drug Administration of China approved JHL's phase I and phase III clinical trial application; it will begin trials "in the following months" |
7/6/18 |
|
Medical Prognosis Institute, of Hoersholm, Denmark and Oncology Venture Sweden AB |
Liplacis |
Targeted liposomal formulation of cisplatin |
Hard-to-treat metastatic breast cancer |
Company discussed interim phase II data with Danish Medicines Agency and proposed pivotal trial design; regulators indicated that the planned trial will be considered a pivotal phase II study if accepted for the EMA PRIME program |
7/2/18 |
|
Merck & Co. Inc., of Kenilworth, N.J. |
Keytruda (pembrolizumab) |
PD-1-targeting antibody |
Urothelial cancer |
FDA posted its June 19 action in which it limited the drug's use to patients with locally advanced or metastatic disease who are not eligible for cisplatin-containing therapy; decision was based on data showing decreased survival with Tecentriq as a monotherapy vs. platinum-based chemotherapy in patients who have not received prior therapy and have low expression of PD-L1 |
7/3/18 |
|
Merck & Co. Inc., of Kenilworth, N.J. |
Keytruda (pembrolizumab) |
Anti-PD-1 antibody |
Advanced hepatocellular carcinoma |
FDA accepted the supplemental BLA seeking accelerated approval and granted priority review; PDUFA date is Nov. 9, 2018 |
7/11/18 |
|
Merck & Co. Inc., of Kenilworth, N.J. |
Keytruda (pembrolizumab) |
Anti-PD-1 antibody |
Unresectable or metastatic melanoma |
Approved by the China National Drug Administration for use in adults following failure of 1 prior line of therapy |
7/26/18 |
|
Merck & Co. Inc., of Kenilworth, N.J. |
Keytruda (pembrolizumab) |
Anti-PD-1 antibody |
First-line metastatic nonsquamous non-small-cell lung cancer |
EMA's CHMP recommended approval in combination with pemetrexed and platinum chemotherapy in adults whose tumors have no EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression |
7/30/18 |
|
Merck & Co. Inc., of Kenilworth, N.J. |
Keytruda (pembrolizumab) |
Anti-PD-1 antibody |
Metastatic squamous non-small-cell lung cancer |
FDA accepted for priority review the supplemental BLA seeking approval in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment, regardless of PD-L1 expression; PDUFA date is Oct. 30, 2018 |
7/2/18 |
|
Merck KGaA, of Darmstadt, Germany |
Euthyrox (levothyroxine) |
Synthetically produce hormone corresponding to thyroxin |
Hyperpara-thyroidism, goiter and to suppress TSH in post-treatment of differentiated thyroid cancer |
German Federal Institute for Drugs and Medical Devices recommended approval of the new formulation in 21 EU countries |
7/26/18 |
|
Mersana Therapeutics Inc., of Cambridge, Mass. |
XMT-1522 |
Antibody-drug conjugate targeting HER2-expressing tumors |
HER2-positive breast and gastric cancers, advanced breast cancer with low HER2 expression and non-small-cell lung cancer |
FDA placed a phase I study on partial clinical hold; no new patients will be enrolled, though current study participants will continue to receive drug and otherwise participate in the trial consistent with protocol; hold was initiated following report of a grade 5 serious adverse event (patient death) in dose level 7 that was classified as possibly drug-related |
7/19/18 |
|
Novartis AG, of Basel, Switzerland |
Tafinlar (dabrafenib) plus Mekinist (trametinib) |
BRAF kinase inhibitor plus MEK1/2 inhibitor |
Adjuvant treatment of stage III melanoma with BRAFV600 mutation |
EMA's CHMP recommended approval for use in adults following complete resection |
7/27/18 |
|
Oasmia Pharmaceutical AB, of Uppsala, Sweden |
Apealea |
Cremophor- and albumin-free formulation of paclitaxel |
Epithelial ovarian cancer |
Company decided to withdraw EMA orphan medicine application following new prevalence data; Apealea designated orphan drug by the EC in 2006; company also disclosed that the EMA's CHMP determined that the remaining list of outstanding issues must be addressed for the pending MAA |
7/27/18 |
|
Pfizer Inc., of New York |
Trazimera |
Biosimilar to Herceptin (trastuzumab) |
HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma |
EC granted marketing authorization |
7/31/18 |
|
Progenics Pharmaceuticals Inc., of New York |
Azedra (iobenguane I 131) |
Radiolabeled guanidine analog |
Lobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma |
FDA approved the NDA |
7/30/18 |
|
Puma Biotechnology Inc., of Los Angeles |
Nerlynx (neratinib) |
Pan-HER kinase inhibitor |
Extended adjuvant treatment of early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy |
Health Canada accepted the new drug submission for review |
7/31/18 |
|
Roche Holding AG, of Basel, Switzerland |
Tecentriq (atezolizumab) plus Avastin (bevacizumab) |
Anti-PD-L1 and anti-VEGF antibodies |
First-line treatment of advanced or metastatic hepatocellular carcinoma |
FDA granted breakthrough therapy designation for the combination |
7/18/18 |
|
Roche Indonesia, of Jakarta, Indonesia, a unit of Roche Holding AG |
Subcutaneous trastuzumab |
HER2-targeting antibody |
HER2-positive breast cancer |
Approved by Indonesia's National Agency of Drug and Food Control |
7/11/18 |
|
Sellas Life Sciences Group Inc., of New York |
Galinpepimut-S |
Heteroclitic multivalent, multipeptide cancer immunotherapeutic agent |
Multiple myeloma |
FDA granted fast track status |
7/20/18 |
|
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan |
DSP-1958 |
Thiotepa |
Solid tumors |
Submitted NDA in Japan for conditioning treatment prior to autologous hematopoietic stem cell transplantation in pediatric solid tumors |
7/5/18 |
|
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan |
Alunbrig (brigatinib) |
ALK inhibitor |
ALK-positive metastatic non-small-cell lung cancer |
Approved by Health Canada for use as a monotherapy in adults whose disease has progressed on or who were intolerant to an ALK inhibitor |
7/30/18 |
|
The Janssen Pharmaceutical Cos. of Johnson & Johnson, of New Brunswick, N.J. |
Erleada (apalutamide) |
Androgen receptor inhibitor |
Prostate cancer |
Health Canada approved as an oral tablet for patients with nonmetastatic castration-resistant prostate cancer; product was granted priority review |
7/5/18 |
|
Cardiovascular | ||||||
United Therapeutics Corp., of Silver Spring, Md. |
Remodulin (treprostinil) |
Prostacyclin vasodilator |
Pulmonary arterial hypertension |
FDA approved he NDA |
7/31/18 |
|
Dermatologic | ||||||
Aclaris Therapeutics Inc., of Wayne, Pa. |
ATI-502 |
Topical JAK1/3 inhibitor |
Alopecia areata |
FDA granted fast track designation for alopecia areata, including patchy alopecia areata and more severe variants alopecia totalis and universalis |
7/9/18 |
|
Almirall SA, of Barcelona, Spain |
Tildrakizumab |
Anti-interleukin-23 antibody |
Moderate to severe chronic plaque psoriasis |
Received positive opinion from the EMA's CHMP |
7/27/18 |
|
Aslan Pharmaceuticals Pte Ltd., of Singapore |
ASLAN-004 |
Fully human monoclonal antibody targeting IL-13 receptor alpha1 subunit |
Atopic dermatitis |
Submitted a clinical trial authorization application with the Singapore Health Sciences Authority for a phase I trial |
7/3/18 |
|
Biopharmax Corp., of Menlo Park, Calif. |
BPX-01 |
Topical gel formulation of minocycline |
Inflammatory acne |
FDA waived the requirement for a dermal carcinogenicity study, eliminating several years of nonclinical research normally required for review |
7/19/18 |
|
Endocrine/Metabolic | ||||||
Aegerion Pharma-ceuticals Inc., of Windsor, U.K., a unit of Novelion Therapeutics Inc., of Vancouver, British Columbia |
Myalepta (metreleptin) |
Leptin replacement therapy |
Lipodystrophy |
EC granted marketing authorization |
7/31/18 |
|
Alnylam Pharmaceuticals Inc., of Cambridge, Mass. |
Patisiran |
RNAi therapeutic targeting transthyretin |
Hereditary transthyretin-mediated amyloidosis |
EMA's CHMP recommended approval in adults with stage 1 or stage 2 polyneuropathy; if approved, drug will be sold under the brand Onpattro |
7/27/18 |
|
Amarin Corp. plc, of Dublin |
Vascepa (icosapent ethyl) |
Highly-pure, omega-3 fatty acid product |
Adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia |
Approved by the United Arab Emirates Ministry of Health and Prevention |
7/26/18 |
|
Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis |
Jardiance (empagliflozin), Synjardy (empagliflozin/metformin) and Glyxambi (empagliflozin/linagliptin) |
SGLT2 inhibitor-based therapies |
Type 2 diabetes |
EMA's CHMP recommended label updates to include additional data from the EMPA-REG OUTCOME trial on heart failure and kidney endpoints, specifically a relative risk reduction in hospitalization for heart failure by 35% and a relative risk reduction for new-onset or worsening of kidney disease by 39% |
7/2/18 |
|
Dicerna Pharmaceuticals Inc., of Cambridge, Mass. |
DCR-PHXC |
Next-generation RNAI product developed using Galxc technology |
Primary hyperoxaluria |
EMA's CHMP recommended orphan designation |
7/11/18 |
|
Eli Lilly and Co., of Indianapolis |
Trulicity (dulaglutide) |
GLP-1 receptor agonist |
Type 2 diabetes |
U.S. label updated to include safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease, based on data from the AWARD-7 trial |
7/19/18 |
|
Ferring Pharmaceuticals Inc., of Parsippany, N.J. |
Zomacton (somatropin) |
Recombinant human growth hormone |
Growth failure in pediatric patients due to inadequate secretion of endogenous growth hormone and replacement of endogenous GH in adults with GH deficiency |
4 pediatric indications approved by FDA: idiopathic short stature; short stature associated with Turner syndrome; short stature born small for gestational age with no catch-up growth by 2 to 4 years; and short stature or growth failure in short stature homeobox-containing gene deficiency |
7/20/18 |
|
Fortress Biotech Inc., of New York |
Copper histidinate (CUTX-101) |
Subcutaneous injectable formulation intended to improve tolerability due to physiological pH and bypass the oral absorption of copper |
Classic Menkes disease |
FDA granted fast track designation to Fortress subsidiary Cyprium Therapeutics for use in patients who have not demonstrated significant clinical progression |
7/2/18 |
|
Janssen Pharmaceutical Cos., of Raritan, N.J., part of Johnson & Johnson |
Invokana (canagliflozin) |
SGLT2 inhibitor |
Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes |
FDA extended the review timeline for the sNDA, seeking approval in patients who are at risk for CV disease; action date is now in October 2018 |
7/13/18 |
|
Opko Health Inc., of Miami, and Vifor Fresenius Medical Care Renal Pharma Ltd., of Paris |
Rayaldee |
Extended-release prohormone of calcitriol |
Secondary hyperparathyroidism |
Approved by Health Canada for use in adults with stage 3 or 4 chronic kidney disease and vitamin D deficiency |
7/16/18 |
|
Ultragenyx Pharmaceutical Inc., of Novato, Calif. |
DTX-401 |
AAV-based gene therapy |
Glycogen storage disease type 1a |
FDA granted fast track designation |
7/26/18 |
|
Gastrointestinal | ||||||
Aequus Pharmaceuticals Inc., of Vancouver, British Columbia |
AQS-1303 |
Anti-nausea transdermal patch |
Nausea and vomiting during pregnancy |
Received marketing authorization in the U.K. under the brand Xonvea |
7/19/18 |
|
Emmaus Life Sciences Inc., of Torrance, Calif. |
L-glutamine oral powder |
Increases synthesis of glutathione in the intestine |
Diverticulosis |
FDA accepted the IND for a pilot study set to start by the end of 2018 |
7/9/18 |
|
Merz North America Inc., of Raleigh, N.C. |
Xeomin |
Incobotulinum-toxinA |
Sialorrhea (excessive drooling) |
Approved by FDA for use in adults; sBLA was cleared under priority review |
7/3/18 |
|
Genitourinary/Sexual Function | ||||||
Abbvie Inc., of North Chicago, and Neurocrine Biosciences Inc., of San Diego |
Orilissa (elagolix) |
Oral gonadotropin-releasing hormone antagonist |
Moderate to severe endometriosis pain |
Approved by FDA under priority review |
7/24/18 |
|
Hansa Medical AB, of Lund, Sweden |
Imlifidase |
Immunoglobulin G-degrading enzyme of Streptococcus pyogenes |
Anti-GBM antibody disease (Goodpasture disease) |
FDA granted orphan designation |
7/9/18 |
|
Hematologic | ||||||
Accord Healthcare Inc., of Ahmadabad, India |
Pelgraz |
Pegylated G-CSF biosimilar |
Neutropenia |
EMA's CHMP issued a positive opinion for use of the drug to reduce duration of neutropenia and the incidence of febrile neutropenia in adults undergoing cytotoxic chemotherapy |
7/27/18 |
|
Bluebird Bio Inc., of Cambridge, Mass. |
Lentiglobin |
Gene therapy |
Transfusion-dependent beta-thalassemia and a non-β0/β0 genotype |
EMA's CHMP granted accelerated assessment; company intends to file MAA in 2018 |
7/27/18 |
|
Coherus Biosciences Inc., of Redwood City, Calif. |
Udenyca (CHS-1701) |
Pegfilgrastim biosimilar |
Neutropenia |
EMA's CHMP issued a positive opinion |
7/27/18 |
|
CTI Biopharma Corp., of Seattle |
Pacritinib |
Inhibitor of JAK2, FLT3, IRAK1 and CSF1R |
Myelofibrosis |
After getting advice in a type B meeting with the FDA, company plans to run a phase III study starting in 2019 |
7/18/18 |
|
Pfizer Inc., of New York |
Nivestym (filgrastim-aafi) |
Biosimilar of Neupogen (filgrastim) |
Neutropenia |
Approved by FDA for all eligible indications of the reference product |
7/20/18 |
|
Portola Pharmaceuticals Inc., of South San Francisco |
Betrixaban |
Once-daily factor Xa inhibitor |
Prevention of venous thromboembolism |
EMA's CHMP maintained its negative opinion following a re-examination procedure requested by the company; MAA seeks approval for use in adults hospitalized with acute medical illness with risk factors for VTE |
7/27/18 |
|
Shire plc, of Dublin |
Veyvondi (vonicog alfa) |
Recombinant von Willebrand factor |
Bleeding events and treatment/prevention of surgical bleeding in von Willebrand disease patients |
EMA's CHMP recommended approval for treating adults when desmopressin treatment alone is ineffective or not indicated |
7/2/18 |
|
Immune | ||||||
Cellix Biosciences Inc., of Newark, N.J. |
CLX-106 |
Molecular conjugate designed to deliver monomethyl fumarate |
Relapsing-remitting multiple sclerosis |
FDA confirmed the 505(b)(2) pathway is appropriate |
7/11/18 |
|
Enzyvant Sciences GmbH, of Basel, Switzerland |
RVT-802 |
Tissue-based regenerative therapy |
Primary immune deficiency resulting from congenital athymia associated with complete DiGeorge anomaly |
Initiated a rolling BLA to the FDA; company expects to complete submission by the end of 2018 |
7/9/18 |
|
Gamida Cell Ltd., of Tel Aviv, Israel |
Nicord |
Ex vivo expanded cell graft derived from umbilical cord stem cells |
Hematopoietic stem cell transplantation |
FDA granted orphan designation |
7/17/18 |
|
Merck KGaA, of Darmstadt, Germany |
Cladribine tablets |
Activated by lymphocytes |
Relapsing multiple sclerosis |
Resubmission of NDA accepted for filing by FDA |
7/30/18 |
|
Mylan NV, of Hertfordshire, U.K., and Fujifilm Kyowa Kirin Biologics Co. Ltd., of Tokyo |
Hulio (FKB-327) |
Biosimilar to TNF-alpha inhibitor Humira (adalimumab) |
Rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, et al. |
EMA's CHMP adopted a positive opinion for the biosimilar for all reference drug indications |
7/27/18 |
|
Nohla Therapeutics Inc., of Seattle |
Dilanubicel (NLA-101) |
Off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell therapy |
Reduction of morbidity and mortality associated with hematopoietic stem cell transplant |
FDA granted orphan designation |
7/16/18 |
|
Sandoz, a unit of Basel, Switzerland-based Novartis AG |
Hyrimoz (adalimumab) |
Biosimilar of anti-TNF-alpha antibody |
Rheumatoid arthritis, plaque psoriasis, Crohn's disease, uveitis, ulcerative colitis, et al. |
EC granted marketing approval for use in all indications of the reference drug |
7/27/18 |
|
Infection | ||||||
60 Degrees Pharmaceuticals LLC, of Washington |
Arakoda (tafenoquine) |
8-aminoquinoline chemically derived from Primaquine |
Prevention of malaria |
FDA's Antimicrobial Drugs Advisory Committee voted 11-2 to support the drug's efficacy and 9-4 in favor of its safety |
7/26/18 |
|
Adma Biologics Inc., of Ramsey, N.J. |
Bivigam |
Intravenous immune globulin (human) |
Prevention and treatment of certain infectious diseases |
FDA acknowledged receipt of the prior approval supplement filing for review, seeking approval to amend use for Bivigam; if approved, Adma plans to relaunch the product in the U.S.; target action date is Oct. 25, 2018; the company also reported that the FDA closed its manufacturing inspection for the Boca Raton, Fla.-based facility |
7/26/18 |
|
Ascletis Bioscience Co. Ltd., of Hangzhou, China |
Ravidasvir |
NS5A inhibitor |
Hepatitis C |
Filed a new drug application with the China FDA for use in combination with Ganovo |
7/31/18 |
|
Cellerant Therapeutics Inc., of San Carlos, Calif. |
Romyelocel-L |
Human myeloid progenitor cells |
Prevention of serious bacterial and fungal infections in de novo acute myeloid leukemia patients undergoing induction chemotherapy |
FDA granted regenerative medicine advanced therapy designation |
7/2/18 |
|
Gilead Sciences Inc., of Foster City, Calif. |
Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) |
Once-daily, single-tablet regimen comprising an integrase strand transfer inhibitor with dual nucleoside reverse transcriptase inhibitor backbone |
HIV-1 infection |
Approved by Health Canada |
7/12/18 |
|
Glaxosmithkline plc, of London |
Krintafel (tafenoquine) |
8-aminoquinoline derivative |
Prevention of relapse of Plasmodium vivax malaria |
Approved by FDA under priority review for use in patients, 16 and older, who are receiving appropriate antimalarial therapy for acute P. vivax infection |
7/20/18 |
|
Janssen Pharmaceutical Co. of New Brunswick N.J.-based Johnson & Johnson |
Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) |
Single-tablet regimen |
HIV-1 in treatment-naïve and certain virologically suppressed adults |
FDA approved the drug |
7/17/18 |
|
Siga Technologies Inc., of New York |
Tpoxx (tecovirimat) |
Antiviral |
Smallpox |
Approved by FDA; awarded a material threat medical countermeasure priority review voucher |
7/13/18 |
|
Tetraphase Pharmaceuticals Inc., of Watertown, Mass. |
Xerava (eravacycline) |
Fully synthetic fluorocycline antibiotic |
Complicated intra-abdominal infections |
EMA's CHMP recommended approval in adults; EC expected to make final decision within 3 months |
7/28/18 |
|
Theratechnologies Inc., of Montreal |
Egrifta (tesamorelin) |
Stimulates growth hormone secretion |
HIV-associated lipodystrophy |
Filed an sNDA with FDA for a single-vial formulation that is 4 times more concentrated than the currently commercialized formulation |
7/5/18 |
|
Theratechnologies Inc., of Montreal |
Trogarzo |
Ibalizumab-uiyk |
HIV |
EMA will review the application for marketing authorization of Trogarzo injection under the accelerated assessment procedure |
7/31/18 |
|
Utility Therapeutics Ltd., of London |
Pivmecillinam |
Beta-lactam antibiotic |
Uncomplicated urinary tract infection |
Designated a qualified infectious disease product by the FDA |
7/16/18 |
|
Inflammatory | ||||||
Corbus Pharmaceuticals Holdings Inc., of Norwood, Mass. |
Lenabasum |
Synthetic oral endocannabinoid-mimetic drug |
Dermatomyositis |
FDA granted orphan designation |
7/20/18 |
|
Kolon Tissuegene Inc., of Rockville, Md. |
Invossa |
Allogeneic cell and gene therapy |
Knee osteoarthritis |
FDA lifted the clinical hold so firm can move forward with phase III trials |
7/6/18 |
|
Taiwan Liposome Co. Ltd., of Taipei, Taiwan |
TLC-599 |
Bioseizer formulation of dexamethasone sodium phosphate |
Mild to moderate knee osteoarthritis |
Cleared by FDA to begin a phase II, open-label, pharmacokinetic trial; enrollment set to start in the fourth quarter of 2018 |
7/9/18 |
|
Musculoskeletal | ||||||
Acceleron Pharma Inc., of Cambridge, Mass. |
ACE-083 |
Locally acting drug based on follistatin |
Facioscapulo-humeral muscular dystrophy |
FDA granted orphan designation |
7/12/18 |
|
Innovent Biologics Inc., of Suzhou, China |
IBI-307 |
Anti-RANKL antibody |
Osteoporosis and lytic bone lesions associated with cancer metastasis |
Received IND approval from Chinese regulators |
7/26/18 |
|
Inozyme Pharma Inc., of Boston |
INZ-701 |
Enzyme replacement therapy |
ENPP1 deficiency |
FDA granted orphan designation |
7/17/18 |
|
Nektar Therapeutics Inc., of San Francisco |
NKTR-181 |
Long-acting, selective full mu-opioid receptor agonist |
Chronic low back pain |
FDA accepted for review the NDA seeking approval for use in adults new to opioid therapy; PDUFA date expected to be May 28, 2019 |
7/30/18 |
|
Wave Life Sciences Ltd., of Cambridge, Mass. |
WVE-210201 |
Stereopure oligonucleotide designed to induce skipping of exon 51 of dystrophin |
Duchenne muscular dystrophy |
EMA's CHMP issued positive opinion for orphan designation |
7/2/18 |
|
Neurology/Psychiatric | ||||||
Alkermes plc, of Dublin |
Aristada Initio (aripiprazole lauroxil) |
Long-acting injectable atypical antipsychotic |
Schizophrenia |
Approved by FDA for use in adults |
7/2/18 |
|
Allergan plc, of Dublin |
AGN-241751 |
Oral, small-molecule N-methyl-D-aspartate receptor modulator |
Major depressive disorder |
FDA granted fast track designation |
7/23/18 |
|
Asceneuron SA, of Asceneuron, Switzerland |
ASN-120290 |
O-GlcNAcase inhibitor |
Progressive supranuclear pals |
FDA granted orphan drug designation |
7/18/18 |
|
Durect Corp., of Cupertino, Calif., and Indivior, of Slough, U.K. |
Perseris (risperidone, RBP-700) |
Long-acting antipsychotic |
Schizophrenia |
Approved by FDA for use in adults |
7/30/18 |
|
Insys Therapeutics Inc., of Phoenix |
Buprenorphine sublingual spray |
Binds to opioid receptors |
Moderate to severe acute pain |
Received a complete response letter from the FDA; company is assessing next steps |
7/27/18 |
|
Ironshore Pharmaceuticals & Development Inc., of George Town, Grand Cayman |
HLD-200 |
Delayed-release and extended-release methylphenidate |
Attention deficit hyperactivity disorder |
FDA accepted for review the NDA and set a PDUFA date of Aug. 8, 2018 |
7/13/18 |
|
Luye Pharma Group, of Shanghai |
Seroquel XR (quetiapine fumarate) |
Atypical antipsychotic |
Depression arising from bipolar disorder |
Received approval in China for the new indication |
7/23/18 |
|
Neurim Pharmaceuticals Ltd., of Tel Aviv, Israel |
Slenyto |
Pediatric prolonged-release melatonin coated tablets |
Insomnia |
EMA's CHMP recommended approval for use in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome |
7/30/18 |
|
Novartis AG, of Basel, Switzerland |
Aimovig (erenumab) |
CGRP-R inhibitor |
Prevention of migraine in adults experiencing 4 or more migraine days per month |
EC granted marketing authorization |
7/30/18 |
|
Painreform Ltd., of Herzliya, Israel |
PRF-110 |
Extended-release ropivacaine |
Postoperative pain |
FDA gave approval to run 2 pivotal studies |
7/18/18 |
|
Pharnext SA, of Paris |
PXT-3003 |
Low-dose fixed combination of baclofen, naltrexone and sorbitol |
Charcot-Marie-Tooth disease type 1A |
EMA agreed with the firm's pediatric investigation plan |
7/10/18 |
|
Reata Pharmaceuticals Inc., of Irving, Texas |
Omaveloxolone |
Oral, once-daily activator of Nrf2 |
Friedreich's ataxia |
EC granted orphan drug designation |
7/11/18 |
|
Sedor Pharmaceuticals LLC, of Paoli, Pa. |
I.M./I.V. Captisol-enabled fosphenytoin |
Fosphenytoin, sodium and sulfobutylether beta cyclodextrin sodium for injection |
Generalized tonic-clonic status epilepticus/prevention and treatment of seizures during neurosurgery/short-term use for oral phenytoin |
FDA accepted the 505(b)(2) NDA |
7/30/18 |
|
Sumitomo Dainippon Pharma Co. Ltd. and Nitto Denko Corp., both of Osaka, Japan |
Lonasen (blonanserin) |
Atypical antipsychotic |
Schizophrenia |
Submitted NDA in Japan for a transdermal patch formulation of the drug |
7/31/18 |
|
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan |
Trerief (zonisamide) |
Antiepileptic |
Parkinsonism in dementia with Lewy bodies |
Approved in Japan |
7/2/18 |
|
Tonix Pharmaceuticals Holding Corp., of New York |
TNX-102 SL |
Cyclobenzaprine HCl sublingual tablets |
Agitation in Alzheimer's disease |
FDA granted fast track designation |
7/16/18 |
|
Voyager Therapeutics Inc., of Cambridge, Mass. |
VY-AADC |
Gene therapy designed to deliver AADC gene |
Parkinson's disease patients with motor fluctuations refractory to medical management |
Reported feedback from a type C meeting with the FDA; agency indicated in a written response that the phase II study in about 42 patients, if it meets its primary endpoint of demonstrating a statistically significant difference of diary on-time without dyskinesia vs. the placebo surgery group and in the absence of major safety concerns, likely may be considered sufficient for BLA submission; if phase II data are supportive only, the randomized, placebo-controlled phase III trial in about 120 patients, if it achieves its primary endpoint, also likely may be considered sufficient for a BLA |
7/17/18 |
|
Ocular | ||||||
Aerie Pharmaceuticals Inc., of Durham, N.C. |
Roclatan (netarsudil/latanoprost ophthalmic solution 0.02%/0.005%) |
Rho kinase inhibitor/prostaglandin analogue |
Reducing intraocular pressure in glaucoma or ocular hypertension |
Received the day 74 notification from the FDA, which completed its 60-day review of the NDA and determined the application is sufficiently complete to permit a substantive review; the PDUFA date is March 14, 2019 |
7/23/18 |
|
Apellis Pharmaceuticals Inc., of Crestwood, Ky. |
APL-2 |
Inhibitor of complement factor C3 |
Geographic atrophy |
FDA granted fast track status in GA, an advanced form of age-related macular degeneration |
7/24/18 |
|
Ocular Therapeutix Inc., of Bedford, Mass. |
Dextenza |
Dexamethasone insert 0.4 mg |
Ocular pain following ophthalmic surgery |
FDA acknowledged acceptance of the resubmitted NDA; considered a class 2 response to the July 2017 complete response letter; PDUFA date is Dec. 28, 2018 |
7/19/18 |
|
Other/Miscellaneous | ||||||
Akcea Therapeutics Inc., of Cambridge, Mass., and Ionis Pharmaceuticals Inc., of Carlsbad, Calif. |
Tegsedi (inotersen) |
Antisense oligonucleotide inhibitor of human TTR production |
Stage 1/2 polyneuropathy in adults with hereditary transthyretin amyloidosis |
Received marketing authorization from the EC |
7/11/18 |
|
Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia |
Scenesse (afamelanotide 16 mg) |
Alpha-melanocyte-stimulating hormone analogue |
Erythropoietic protoporphyria |
Completed NDA submission to the FDA |
7/5/18 |
|
Rhythm Pharmaceuticals Inc., of Boston |
Setmelanotide |
Melanocortin-4 receptor agonist |
Rare genetic disorders of obesity |
EMA granted priority medicines, or PRIME, designation for treatment of obesity and the control of hunger associated with deficiency disorders of the MC4R pathway |
7/23/18 |
|
Soleno Therapeutics Inc., of Redwood City, Calif. |
Diazoxide choline controlled-release |
Extended-release, crystalline salt formulation of diazoxide |
Prader-Willi syndrome |
FDA granted fast track designation |
7/30/18 |
|
Respiratory | ||||||
Glaxosmithkline plc, of London |
Nucala (mepolizumab) |
Monoclonal antibody targeting interleukin-5 |
Chronic obstructive pulmonary disease |
FDA's Pulmonary Allergy Drugs Advisory Committee voted 16-3 that the risk-benefit profile was not adequate to support approval for use as an add-on treatment to reduce exacerbations in COPD |
7/25/18 |
|
Vertex Pharmaceuticals Inc., of Cambridge, Mass. |
Symkevi (tezacaftor/ivacaftor) |
Cystic fibrosis transmembrane conductance regulator corrector/CFTR potentiator |
Cystic fibrosis |
EMA's CHMP recommended approval for people with CF, ages 12 and older, who either have 2 copies of the F508del mutation in the CFTR gene, or 1 copy of the F508del mutation and a copy of 1 of the following 14 mutations: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T |
7/28/17 |
|
Toxicity and Intoxication | ||||||
Braeburn Pharmaceuticals Inc., of Princeton, N.J., and Camurus AB, of Lund, Sweden |
CAM-2038 |
Buprenorphine flexible-dose weekly and monthly subcutaneous depot injection |
Opioid use disorder |
FDA assigned a PDUFA date of Dec. 26, 2018, for the NDA, which has fast track and priority review designations |
7/16/18 |
|
Helsinn Healthcare SA, of Lugano, Switzerland |
Akynzeo (netupitant/palonosetron) |
NK1 receptor antagonist and 5-HT3 receptor antagonist |
Nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy |
Korean Ministry of Food and Drug Safety approved the drug for use |
7/31/18 |
|
Tetra Bio-Pharma Inc., of Orleans, Ontario |
PPP-002 |
Dronabinol Adversa mucoadhesive product |
Chemotherapy-induced nausea and vomiting, anorexia and weight loss in AIDS |
Received two letters from the FDA for type B and type C meetings to discuss requirements for obtaining approval under the 505(b)(2) pathway |
7/26/18 |
|
Notes For more information about individual companies and/or products, see Cortellis. |